August Month in Review: Top Stories on Drug Topics®
Take a look back at our most popular news from August 2022.
Did you miss the top stories on Drug Topics® this month? Catch up on these noteworthy stories today.
10. First Interchangeable Biosimilar to Lucentis Launches
Cimerli can be used for all 5 indications. No information on pricing has been released.
9. Become the Pharmacy of the Future With Technology Solutions
Technology is reshaping the way that health care is delivered. From the physician’s office to the pharmacy, a slew of innovative ideas and solutions are poised to change the way pharmacies interact with their customers and patients.
8. Flu Vaccination and Older Hospitalized Adults with Cardiovascular Disease: What are the Benefits?
A study published in the International Journal of Infectious Diseases found flu vaccines reduced in-hospital deaths and recurrent hospitalizations for older hospitalized adults with cardiovascular disease.
7. Black Patients Have Higher Risk of Vision Loss After Glaucoma Diagnosis
New research examines the disparities in vision loss in glaucoma cases.
A pharmacist reflects on how prescribing behaviors have changed over the years and the potential for stigma linked to providing buprenorphine to patients who need it.
5. Vivjoa Approved for Recurrent Vulvovaginal Candidiasis
Oteseconazole is a treatment option for those living with a previously unmet medical need.
4. Optum Joins Others Offering Affordable Insulin
The company will provide uninsured patients nationwide an avenue for getting the drug at a far more affordable price point.
3. Probiotics for the Prevention of Pediatric Antibiotic-Associated Diarrhea
Evidence of the relationship between probiotics and antibiotics is lacking.
2. Pharmacists Fight to Take on Opioid Use Disorder
Buprenorphine can only be prescribed by pharmacists with waivers, limiting access to this necessary treatment for communities.
1. What's Coming in the 2022-2023 Flu Season
Learn about the selected strains for this year’s flu season, flu vaccine recommendation changes, and newly licensed and forthcoming vaccine options.
